Financials in USD. Standardized financial statements.
A compact view of how Laboratorios Farmaceuticos Rovi, S.A. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $743.20M | $763.75M | $829.51M | $817.70M | $648.68M | $419.96M | $381.31M | $303.20M | $275.65M | $265.17M |
| Revenue Growth? | -2.7% | -7.9% | +1.4% | +26.1% | +54.5% | +10.1% | +25.8% | +10.0% | +4.0% | 0.0% |
| Cost of Revenue? | $291.72M | $296.04M | $346.17M | $305.27M | $268.84M | $182.82M | $169.88M | $132.15M | $113.80M | $115.35M |
| Gross Profit? | $451.48M | $467.71M | $483.34M | $512.43M | $379.83M | $237.14M | $211.43M | $171.06M | $161.84M | $149.81M |
| Gross Margin? | +60.7% | +61.2% | +58.3% | +62.7% | +58.6% | +56.5% | +55.4% | +56.4% | +58.7% | +56.5% |
| Operating Expenses? | $278.40M | $288.17M | $263.09M | $256.58M | $198.44M | $162.45M | $168.59M | $153.60M | $142.84M | $121.52M |
| Operating Income? | $173.08M | $179.54M | $220.25M | $255.85M | $181.39M | $74.68M | $42.84M | $17.46M | $19.01M | $28.30M |
| EBITDA? | $203.44M | $199.62M | $238.02M | $271.33M | $196.56M | $89.61M | $55.44M | $26.98M | $25.42M | $32.62M |
| Income Before Tax | $183.19M | $177.69M | $220.41M | $257.97M | $182.63M | $72.58M | $41.88M | $16.68M | $17.52M | $27.88M |
| Income Tax Expense | $42.88M | $40.81M | $50.11M | $58.30M | $29.55M | $11.52M | $2.61M | -$1.22M | $281,000 | $1.79M |
| Net Income? | $140.39M | $136.88M | $170.34M | $199.67M | $153.08M | $61.06M | $39.27M | $17.89M | $17.24M | $26.09M |
| EPS? | $2.75 | $2.67 | $3.20 | $3.73 | $2.76 | $1.10 | $0.71 | $0.35 | $0.35 | $0.53 |
| Diluted EPS? | $2.75 | $2.67 | $3.20 | $3.73 | $2.76 | $1.10 | $0.71 | $0.35 | $0.35 | $0.53 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality